Ablynx NV (XBRU:ABLXS) Change In Receivables : €-4.48 Mil (TTM As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV Change In Receivables?

Ablynx NV's change in receivables for the quarter that ended in Dec. 2017 was €-5.05 Mil. It means Ablynx NV's Accounts Receivable increased by €5.05 Mil from Jun. 2017 to Dec. 2017 .

Ablynx NV's change in receivables for the fiscal year that ended in Dec. 2017 was €-4.48 Mil. It means Ablynx NV's Accounts Receivable increased by €4.48 Mil from Dec. 2016 to Dec. 2017 .

Ablynx NV's Accounts Receivable for the quarter that ended in Dec. 2017 was €2.11 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ablynx NV's Days Sales Outstanding for the six months ended in Dec. 2017 was 18.44.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ablynx NV's liquidation value for the six months ended in Dec. 2017 was €94.54 Mil.

Ablynx NV Change In Receivables Historical Data

The historical data trend for Ablynx NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Change In Receivables Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Change In Receivables

Get a 7-Day Free Trial

-2.29

-3.96

-11.65

0.09

-4.48

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
Change In Receivables	Get a 7-Day Free Trial															-4.71	3.80	-3.71	0.57	-5.05

Ablynx NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-4.48 Mil.

Ablynx NV (XBRU:ABLXS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ablynx NV's Days Sales Outstanding for the quarter that ended in Dec. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.111	/	20.897	*	91
=	18.44

2. In Ben Graham's calculation of liquidation value, Ablynx NV's accounts receivable are only considered to be worth 75% of book value:

Ablynx NV's liquidation value for the quarter that ended in Dec. 2017 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	302.947	-	209.992	+	0.75 * 2.111	+	0.5 * 0
=	94.54

Ablynx NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines